Sleep better
with Snoozeal®

Snoozeal® is the world’s first daytime therapy proven to strengthen weak tongue muscles known to be the root cause of sleep apnoea and snoring

When we sleep our tongue and throat muscles are known to relax and cause snoring.

In some people, these over relaxed muscles cause the tongue to fall back in the mouth, partially blocking the airway and resulting in snoring. Snoring deprives the body of quality sleep and can also create problems in relationships, such as sleeping in separate rooms.

partially blocked airway during sleep causes snoring
Snoring is caused by vibrations in the soft tissue in the mouth and throat as you breathe.

Loud snoring often indicates the first stages of a serious medical condition called sleep apnoea.

Sleep apnoea causes the sleeper to stop and start breathing during sleep, often jolting them awake. Night after night of this, interrupted sleep can have a big impact on quality of life and health. In particular, there is a strong clinically proven link between sleep apnoea and comorbidities like diabetes, hypertension and strokes.1-9

collapsed airway due to relaxed muscles
Obstructive sleep apnoea is caused by a fully obstructed airway interrupting breathing and sleep.

Now there is a new way to target the root cause of snoring and mild sleep apnoea.

Snoozeal® is a daytime therapy that uniquely targets the root cause of snoring and mild sleep apnoea by using safe electrical currents to stimulate and improve muscle function in the mouth and tongue.

snoozeal targets tongue muscles
Snoozeal® stimulates tongue muscles, effectively giving them a “work out”

So that you regain good quality sleep and a healthier life.

The strengthened tongue muscle no longer blocks the airway at night, allowing for a restful night’s sleep. The body can rest, recharge and repair itself. You wake up bright, refreshed and ready to face the day.

airway open due to strengthened tongue muscle
Stronger tongue muscles reduce snoring long term

Snoozeal® – The only clinically proven daytime solution to treat snoring and mild sleep apnoea10-12

snoozeal main product
98%
of patients reported reduction in snoring time12
82%
of bed partners reported reduction of their partners snoring12
c. 70%
of sleep apnoea patients achieved reduction in sleep apnoea measures12

Meet Snoozeal®

snoozeal mouth piece

Mouthpiece

Comfortable, one size fits all silicone mouthpiece precisely delivers safe electrical currents to the tongue muscle.

snoozeal control unit

Control unit

The rechargeable control unit attaches to the mouthpiece via a USB connection and is driven by the Bluetooth remote control or Snoozeal® App for maximum freedom during use.

snoozeal app

The App

Follow and control your therapy, track changes in your snoring.

snoozeal remote control

Remote control

Or use the remote to simply select the stimulation level that suits you best.

Award winning
product design

Winner of The iF Design Award 2020 for Design
Excellence in the ‘Medical Device’ category.

iF Design award 2020

Easy to treat, maintain and track

20 minutes icon

Use for 20 minutes every day, during the day for 6 weeks

treatment plan icon

Use once a week for 20 minutes to keep your tongue muscles toned

track icon

Monitor progress and track results with the Snoozeal® App

Follow your treatment plan

snoozeal app settings phone screengrab

Track progress and see improvements

snoozeal app on phone screengrab

Share your data with your doctor

snoozeal app awards mobile phone screengrab
how snoozeal works - hand with device

Clinically proven to
significantly reduce snoring
and mild sleep apnoea 1-3

“Treatment of sleep apnoea can be highly effective for some patients as it has been shown to improve symptoms, reduce blood pressure, reduce the risk of motor vehicle accidents, among other benefits. A strong argument can be made that early treatment may be beneficial since the consequences of disease may become irreversible if the disease is longstanding. Thus, treatment of patients with mild OSA and/or at young ages may be a useful strategy.

I have been involved with the Snoozeal® device and have been doing ongoing research on this treatment. I am optimistic that this treatment will be an important treatment approach for patients with snoring and with mild sleep apnoea.”

professor atul malhotra

Professor Atul Malhotra

M.D. Research Chief, Pulmonary, Critical Care and Sleep Medicine
Peter C. Farrell Presidential Chair and Professor in Respiratory Medicine
Former President, American Thoracic Society 2015- 2016

“My practice is limited to treating patients with sleep disorders such as snoring, obstructive sleep apnoea (OSA) and sleep bruxism. The tongue is often the reason I struggle to provide a total resolution of symptoms with a Mandibular Advancement Device for my patients who are snorers and apnoeacs, mild to severe. This is a result of the multifactorial nature of the disease.

Snoozeal® has given me the additional treatment option I have been looking for to achieve complete success. Snoozeal®, a 20 min daytime treatment primarily for snoring and mild OSA, has the potential to increase the efficiency of a Mandibular Advancement Device. The technology is sophisticated and I can see this being easily accepted by snorers and mild apnoea patients who may want to give themselves an occasional break from using a device at night as the lasting effect of the treatment can reduce snoring and daytime symptoms (daytime sleepiness, fatigue, irritability).  In mild cases it may be the ultimate treatment option without the need for any further intervention.”

dr aditi desai

Dr Aditi Desai

Consultant Dental Surgeon with special interest in Sleep Medicine
President of the British Society of Dental Sleep Medicine (BSDSM)
President And Co-Founder of the British Academy of Dental Sleep Medicine (BADSM)
Member of the Board of the Association for Respiratory Technology and Physiology, UK (ARTP)
Council of Sleep Medicine and Odontology Section of Royal Society of Medicine.(RSM)

With improved sleep quality comes better health, better lives and closer relationships

References

  1. White DP, Sleep-related breathing disorder: 2-pathophysiology of obstructive sleep apnoea. Thorax. 1995; 50:797-804. [PubMed: 7570420]
  2. Peppard PE, Young T, Palta M et al. Prospective study of the association between sleep disordered breathing and hypertension. N Engl J Med 2000; 1378-1384. [PubMEd: 10805822]
  3. Gottlieb DJ, Yenokyan G, Newman AB, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. Circulation. 2010;122:352-360. [PubMed: 20625114]
  4. Yaggi HK, Concato J, Kernan WN, et al. Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med. 2005;353:2034-2041. [PubMed: 16282178]
  5. Redline S, Yenokyan G, Gottlieb DJ, et al. Obstructive sleep apnea-hypopnea and incident stroke: The Sleep Heart Health Study. AM J Respir Crit Care Med. 2010; 182:269-277. [PubMed: 20339144]
  6. Peker Y, Hedner J, Norum J, et al. Increased incidence of cardiovascular disease in middle-aged men with obstructive sleep apnea: a 7-year follow-up. AM J Repir Crit Care Med. 2002; 166:159-165. [PubMed: 12119227]
  7. Marin JM, Carrizo SJ, Vicente E, et al Long-term cardiovascular outcomes in men with obstructive sleep apnea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet. 2005; 365:1046-1053. [PubMed: 15781100]
  8. Peppard PE, Szklo-Coxe M, Hla KM, et al. Longitudinal association of sleep-related breathing disorder and depression. Arch Intern Med. 2006; 166:1709-1715. [PubMed: 16983048]
  9. Kendzerska T, Gershon AS, Hawker G, et al. Obstructive sleep apnea and incident diabetes: a historical cohort study. AM J Respir Crit Care Med. 2014; 190:218-225. [PubMed: 24897551]
  10. E.Wessoleck et al. Intraoral electrical muscle stimulation in the treatment of snoring. Somnologie (Berl). 2018; 22(Suppl 2): 47–52.
  11. A.Sama et al. Daytime Intraoral Neurostimulation with Snoozeal® for treatment of Snoring and Mild Sleep Apnea. CHEST Annual Meeting Notes, 2018
  12. Prospective cohort study of 50 patients with snoring or mild OSA (Apnea- Hypopnea Index (AHI) <15) with 46 completed the trial. Objective snoring and respiratory parameters were recorded with 2 consecutive WatchPat night sleep studies before and after the use of the device. An intra-oral tongue stimulator (Snoozeal®) device was used for 20mins, once a day for 6-week period